A Post-Hoc Analysis Of Asthma Control And Lung Function Following Treatment With Ciclesonide 80 μg HFA-MDI Twice Daily In Subjects With Mild-to-Moderate Persistent Asthma Previously Receiving Low Dose Fluticasone Propionate/Salmeterol

OBJECTIVE: To evaluate the relative clinical superiority of increasing the dose of fluticasone propionate versus the addition of salmeterol to low-dose fluticasone propionate for long-term asthma control. DATA SOURCES: Literature was identified by a MEDLINE search (1966–October 2002). Key search terms included asthma, inhalation, corticosteroid, β-adrenergic agonist, and combination drug therapy. DATA SYNTHESIS: Current guidelines for long-term control of asthma include treatment with either inhaled corticosteroids (medium dose) or inhaled corticosteroids (low to medium dose) in combination with a long-acting bronchodilator. Previous studies evaluating salmeterol or formoterol combination therapy with beclomethasone or budesonide have generally produced superior results compared with increasing the dose of the inhaled corticosteroid. Four recent controlled clinical trials have compared the clinical utility of fluticasone propionate monotherapy versus salmeterol/low-dose fluticasone propionate for long-term asthma control in patients with moderate to severe persistent asthma. Based on spirometry data, rescue albuterol use, and symptom scores, the addition of salmeterol to low-dose fluticasone propionate was superior to increasing the dose of fluticasone propionate. CONCLUSIONS: Based on improvements in forced expiratory volume in 1 second, peak expiratory flow, and symptom control, the addition of salmeterol to low-dose fluticasone propionate provides better control of asthma than increasing the dose of fluticasone propionate.

Download Full-text

Association of dietary soy genistein intake with lung function and asthma control: a post-hoc analysis of patients enrolled in a prospective multicentre clinical trial

Primary Care Respiratory Journal ◽

10.4104/pcrj.2012.00073 ◽

2012 ◽

Vol 21 (4) ◽

pp. 398-404 ◽

Cited By ~ 13

Author(s):

Christian Bime ◽

Christine Y Wei ◽

Janet Holbrook ◽

Lewis J Smith ◽

Robert A Wise

Keyword(s):

Clinical Trial ◽

Lung Function ◽

Asthma Control ◽

Multicentre Clinical Trial ◽

Post Hoc Analysis ◽

Post Hoc

Download Full-text

Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study

BMC Pulmonary Medicine ◽

10.1186/s12890-017-0410-x ◽

2017 ◽

Vol 17 (1) ◽

Author(s):

Jean Bousquet ◽

Neil Barnes ◽

Michael Gibbs ◽

Nadeem Gul ◽

Susan A Tomkins ◽

...

Keyword(s):

Fluticasone Propionate ◽

Asthma Control ◽

Post Hoc Analysis ◽

Asian Populations ◽

Post Hoc

Download Full-text

An Evaluation Of Asthma Control And Pulmonary Function Following Treatment With Ciclesonide 80 G Twice Daily In Subjects With Mild-To-Moderate Persistent Asthma Previously Receiving Fluticasone Propionate

10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1299 ◽

2011 ◽

Author(s):

Bruce M. Prenner ◽

Eli O. Meltzer ◽

Shailesh Y. Desai ◽

Bingxia Wang ◽

John Karafilidis ◽

...

Keyword(s):

Fluticasone Propionate ◽

Pulmonary Function ◽

Asthma Control ◽

Persistent Asthma ◽

Moderate Persistent Asthma

Download Full-text

Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population

BMJ Open Respiratory Research ◽

10.1136/bmjresp-2020-000856 ◽

2021 ◽

Vol 8 (1) ◽

pp. e000856 ◽

Cited By ~ 1

Author(s):

Hironori Sagara ◽

Nathalie Barbier ◽

Tsuyoshi Ishii ◽

Hajime Yoshisue ◽

Ivan Nikolaev ◽

...

Keyword(s):

Lung Function ◽

Asthma Control ◽

Inhaled Corticosteroids ◽

High Dose ◽

Asthma Control Questionnaire ◽

Post Hoc Analysis ◽

Asian Patients ◽

Asthma Exacerbations ◽

Post Hoc ◽

Medium Dose

Background and objectiveThe 52-week IRIDIUM study demonstrated the efficacy of indacaterol acetate/glycopyrronium bromide/mometasone furoate (IND/GLY/MF) versus IND/MF and salmeterol xinafoate/fluticasone propionate (SAL/FLU) in patients with symptomatic asthma, despite long-acting β2-agonist/inhaled corticosteroids (LABA/ICS) medium-dose or high-dose, predicted forced expiratory volume in 1 s (FEV1) <80% and at least one exacerbation in the previous year. Here, we present data from a post hoc analysis of the IRIDIUM study in the Asian subpopulation.MethodsThis post hoc analysis evaluated improvements in lung function, asthma control and reduction in asthma exacerbations with IND/GLY/MF medium- (150/50/80 µg) and high-dose (150/50/160 µg) versus IND/MF medium- (150/160 µg) and high-dose (150/320 µg), all one time per day and SAL/FLU high-dose (50/500 µg) two times per day, in Asian patients from the IRIDIUM study.ResultsIn total, 258 patients (IND/GLY/MF medium-dose, 52; IND/GLY/MF high-dose, 52; IND/MF medium-dose, 51; IND/MF high-dose, 51; SAL/FLU high-dose, 52) were included. IND/GLY/MF medium- and high-dose showed greater improvement in trough FEV1 at week 26 versus respective doses of IND/MF (Δ, 100 mL and 101 mL; both p<0.05, respectively), and SAL/FLU high-dose (Δ, 125 mL; p=0.0189, and 136 mL; p=0.0118, respectively), which were maintained over 52 weeks. Both doses of IND/GLY/MF showed greater improvement in morning and evening peak expiratory flow versus respective doses of IND/MF and SAL/FLU high-dose at week 52. The changes in Asthma Control Questionnaire-7 scores from baseline were comparable in all treatment groups. IND/GLY/MF medium- and high-dose showed greater reductions in severe (34%, 69%), moderate or severe (18%, 54%) and all exacerbations (21%, 34%) compared with SAL/FLU high-dose over 52 weeks.ConclusionOne time per day, single-inhaler IND/GLY/MF improved lung function, reduced asthma exacerbations and provided comparable asthma control versus IND/MF and SAL/FLU in Asian patients with inadequately controlled asthma despite LABA/ICS. The results of this analysis were consistent with the overall population in the IRIDIUM study.

Download Full-text

Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study

Arthritis Research & Therapy ◽

10.1186/s13075-021-02535-6 ◽

2021 ◽

Vol 23 (1) ◽

Author(s):

Miao Miao ◽

Xian Xiao ◽

Jiayi Tian ◽

Yunzhi Zhufeng ◽

Ruiling Feng ◽

...

Keyword(s):

Low Dose ◽

Activity Index ◽

Cell Subset ◽

Immunoglobulin M ◽

Controlled Clinical Trial ◽

Double Blind ◽

Post Hoc Analysis ◽

Immune Balance ◽

Cell Balance ◽

Post Hoc

Abstract Objective To investigate the regulation of T follicular regulatory (Tfr) and T follicular (Tfh) cell subtypes by low-dose IL-2 in systemic lupus erythematosus (SLE) in a randomized, double-blind, placebo-controlled clinical trial. Methods A post hoc analysis was performed in a randomized cohort of SLE patients (n=60) receiving low-dose IL-2 therapy (n=30) or placebo (n=30), along with the standard of care treatment. The primary endpoint was the attainment of SLE responder index-4 (SRI-4) at week 12 in the trial. Twenty-three healthy controls were enrolled for T cell subset detection at the same time as the trial. The t-stochastic neighbor embedding (tSNE) analysis of CD4 T subsets based on immune cells flow cytometry markers was performed to distinguish Tfh, Tfh1, Tfh2, Tfh17, and Tfr cell subsets. Results Compared with HC, the frequency of Tfr (CXCR5+PD-1low Treg and CXCR5+PD-1high Treg) cells was significantly reduced, while the pro-inflammatory Tfh cells were increased in patients with SLE. The imbalanced Tfh cell was associated with several pathogenic factors (anti-dsDNA antibodies (r=0.309, P=0.027) and serum IL-17 (r=0.328, P=0.021)) and SLE Disease Activity Index (SLEDAI) score (r=0.273, P=0.052). Decreased CXCR5+PD-1low Treg/Tfh and CXCR5+PD-1low Treg/Tfh17 were both associated with increased immunoglobulin M (IgM) (r=−0.448, P=0.002 and r=−0.336, P=0.024, respectively). Efficacy of low-dose IL-2 therapy was associated with a restored Tfr/Tfh cell balance. Conclusion These data support the hypothesis that promotion of Tfr is associated with decreased disease activities and that low-dose IL-2 therapy can recover Tfr/Tfh immune balance. Trial registration number ClinicalTrials.gov Registries (NCT02465580).

Download Full-text